Feasibility study on the production and marketing of shoe bags

The aim of the study is to determine whether the proposed product, the shoe bag, is feasible taking into account several factors that would affect the business. These factors include: Marketing. The proponents realized that the shoebag is marketable to both males and females belonging to classes A & B, ages 15 to 40. This was revealed when the survey showed that a majority were willing to buy the product if offered. The marketability of the shoebag was further proven when the group tested the hypothesis, after which the results showed its validity. Technical. Based on the time and motion study, the group estimated that they can produce one unit of shoe bag in___hours. The major steps that would be undertaken in the process are as follows: (a) cutting, (b) cross-stitching, (c) and sewing. The entire process will be done using the assembly line method. Management and Legal. The group will form a corporation to facilitate the operation of the business. The corporation will make use of a functional organizational structure. Rules and regulations as well as sanctions were drafted to guide the group in their undertaking. Financial. The members of the group will contribute a total of P 15000.00 as their starting capital. Projected financial statements, budgets and ratios were used to determine the financial viability of the business

International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module

We report the results of an International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2007-December 2012 in 503 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study using the Centers for Disease Control and Prevention's (CDC) U.S. National Healthcare Safety Network (NHSN) definitions for device-associated health care–associated infection (DA-HAI), we collected prospective data from 605,310 patients hospitalized in the INICC's ICUs for an aggregate of 3,338,396 days. Although device utilization in the INICC's ICUs was similar to that reported from ICUs in the U.S. in the CDC's NHSN, rates of device-associated nosocomial infection were higher in the ICUs of the INICC hospitals: the pooled rate of central line–associated bloodstream infection in the INICC's ICUs, 4.9 per 1,000 central line days, is nearly 5-fold higher than the 0.9 per 1,000 central line days reported from comparable U.S. ICUs. The overall rate of ventilator-associated pneumonia was also higher (16.8 vs 1.1 per 1,000 ventilator days) as was the rate of catheter-associated urinary tract infection (5.5 vs 1.3 per 1,000 catheter days). Frequencies of resistance of Pseudomonas isolates to amikacin (42.8% vs 10%) and imipenem (42.4% vs 26.1%) and Klebsiella pneumoniae isolates to ceftazidime (71.2% vs 28.8%) and imipenem (19.6% vs 12.8%) were also higher in the INICC's ICUs compared with the ICUs of the CDC's NHSN